The purpose of this study is to determine if 0.5% Ivermectin Cream is a safe and effective treatment for head lice infestations.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
410
Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Cactus Kids Pediatrics
Yuma, Arizona, United States
Universal Biopharma Research, Inc
Dinuba, California, United States
Lice Source Services, Inc.
Plantation, Florida, United States
LSRN
West Palm, Florida, United States
Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success defined as absence of live lice, was assessed in index participants, defined as the youngest person within each household who had at least 3 live lice present at Screening (Day 1). Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Percentage of All Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Treatment success, defined as absence of live lice, was assessed in all subjects. Treatment success was assessed by last observation carried forward (LOCF) imputation and treatment failure imputation.
Time frame: Day 2 up to Day 15 post-application
Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Severity of the adverse events were defined and classified as follows: 'Mild' - Awareness of signs or symptoms, but easily tolerated; 'Moderate' - Discomfort to a degree that adverse event/adverse drug reaction causes interference with normal daily life activities and/or requires medication; 'Severe' - Incapacity with regard to work or usual daily life activities. Requires medical attention/intervention.
Time frame: Day 1 up to Day 15 post-application.
Summary of the Reported Skin/Scalp Irritation Before Treatment and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
Severe skin/scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - large areas of the scalp are red; Severe Excoriation - Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Spence Medical Research
Picayune, Mississippi, United States
Hill Top Research
Miamiville, Ohio, United States
McKenzie Medical Center
McKenzie, Tennessee, United States
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States
Time frame: Day 1 up to Day 15 post-application